

Original Article

Cite this article: van Gennip ACE *et al* (2024). Retinal microvascular function and incidence and trajectories of clinically relevant depressive symptoms: the Maastricht Study. *Psychological Medicine* 1–10. <https://doi.org/10.1017/S0033291724000618>

Received: 20 August 2023

Revised: 5 January 2024

Accepted: 21 February 2024

Keywords:


depressive symptoms; epidemiology; longitudinal study; retinal microvascular function; trajectories; vascular depression

Corresponding author:

Thomas T. van Sloten;

Email: t.t.vansloten@umcutrecht.nl

Retinal microvascular function and incidence and trajectories of clinically relevant depressive symptoms: the Maastricht Study

April C. E. van Gennip^{1,2} , Monideepa D. Gupta^{1,2}, Alfons J. H. M. Houben^{1,2}, Tos T. J. M. Berendschot^{3,4,5}, Carroll A. B. Webers⁴, Marleen M. J. van Greevenbroek^{1,2}, Carla J. H. van der Kallen^{1,2}, Annemarie Koster^{6,7}, Anke Wesselius^{5,8}, Simone J. P. M. Eussen^{2,6,9}, Casper G. Schalkwijk^{1,2}, Bastiaan E. de Galan^{1,2,10}, Sebastian Köhler^{3,11}, Miranda T. Schram^{1,2,3,12}, Coen D. A. Stehouwer^{1,2} and Thomas T. van Sloten¹³

¹Internal Medicine, Maastricht University Medical Centre, Maastricht, Netherlands; ²School for Cardiovascular Diseases, CARIM, Maastricht University, Maastricht, Netherlands; ³School for Mental Health and Neuroscience, MHENS, Maastricht University, Maastricht, Netherlands; ⁴Ophthalmology, Maastricht University Medical Centre, Maastricht, Netherlands; ⁵School of Nutrition and Translational Research in Metabolism, NUTRIM, Maastricht University, Maastricht, Netherlands; ⁶Care and Public Health Research Institute, CAPHRI, Maastricht University, Maastricht, Netherlands; ⁷Social Medicine, Maastricht University, Maastricht, Netherlands; ⁸Genetics and Cell Biology, Maastricht University Medical Centre, Maastricht, Netherlands; ⁹Epidemiology, Maastricht University, Maastricht, Netherlands; ¹⁰Internal Medicine, Radboud University Medical Centre, Nijmegen, Netherlands; ¹¹Psychiatry and Neuropsychology, Maastricht University, Maastricht, Netherlands; ¹²Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, Netherlands and ¹³Vascular Medicine, University Medical Center Utrecht, Utrecht, Netherlands

Abstract

Background. Cerebral microvascular dysfunction may contribute to depression via disruption of brain structures involved in mood regulation, but evidence is limited. We investigated the association of retinal microvascular function, a proxy for microvascular function in the brain, with incidence and trajectories of clinically relevant depressive symptoms.

Methods. Longitudinal data are from The Maastricht Study of 5952 participants (59.9 ± 8.5 years/49.7% women) without clinically relevant depressive symptoms at baseline (2010–2017). Central retinal arteriolar equivalent and central retinal venular equivalent (CRAE and CRVE) and a composite score of flicker light-induced retinal arteriolar and venular dilation were assessed at baseline. We assessed incidence and trajectories of clinically relevant depressive symptoms (9-item Patient Health Questionnaire score ≥10). Trajectories included continuously low prevalence (low, $n = 5225$ [87.8%]); early increasing, then chronic high prevalence (early-chronic, $n = 157$ [2.6%]); low, then increasing prevalence (late-increasing, $n = 247$ [4.2%]); and remitting prevalence (remitting, $n = 323$ [5.4%]).

Results. After a median follow-up of 7.0 years (range 1.0–11.0), 806 (13.5%) individuals had incident clinically relevant depressive symptoms. After full adjustment, a larger CRAE and CRVE were each associated with a lower risk of clinically relevant depressive symptoms (hazard ratios [HRs] per standard deviation [s.d.]: 0.89 [95% confidence interval (CI) 0.83–0.96] and 0.93 [0.86–0.99], respectively), while a lower flicker light-induced retinal dilation was associated with a higher risk of clinically relevant depressive symptoms (HR per s.d.: 1.10 [1.01–1.20]). Compared to the low trajectory, a larger CRAE was associated with lower odds of belonging to the early-chronic trajectory (OR: 0.83 [0.69–0.99]) and a lower flicker light-induced retinal dilation was associated with higher odds of belonging to the remitting trajectory (OR: 1.23 [1.07–1.43]).

Conclusions. These findings support the hypothesis that cerebral microvascular dysfunction contributes to the development of depressive symptoms.

Introduction

Depression is one of the largest contributors to global disability in individuals aged ≥65 years (Empana, Boutouyrie, Lemogne, Jouven, & van Sloten, 2021). Depression has a complex and multifactorial pathophysiology, heterogeneous manifestations, and different courses (or trajectories) over the life span (Musliner, Munk-Olsen, Eaton, & Zandi, 2016). The ‘vascular depression hypothesis’ postulates that cerebrovascular damage may contribute to a specific subtype of depression that may be more common among older individuals and may be characterized by a chronic trajectory (Musliner *et al.*, 2016) and a lower response to current antidepressant

© The Author(s), 2024. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

medication targeting neurotransmitters (Empana *et al.*, 2021). Cerebral microvascular dysfunction may disrupt brain regions involved in mood regulation leading to clinically relevant depressive symptoms (Aizenstein *et al.*, 2016). In accordance, cross-sectional studies have shown that clinically relevant depressive symptoms are associated with reduced cerebrovascular reactivity (Direk *et al.*, 2012) and features of cerebral small vessel disease (Rensma, van Sloten, Launer, & Stehouwer, 2018; van Agtmaal, Houben, Pouwer, Stehouwer, & Schram, 2017), which both may be a result of microvascular dysfunction.

The retina offers a unique opportunity to study cerebral microvascular changes because it allows for non-invasive and easily accessible visualization of a microvascular bed that shares similarities with the cerebral microvasculature (Cheung, Ikram, Chen, & Wong, 2017). Previous studies have found that retinal microvascular measures are associated with features of cerebral small vessel disease (Heringa *et al.*, 2013; Umemura, Kawamura, & Hotta, 2017) and dementia (Cheung, Chan, Mok, Chen, & Wong, 2019). However, data on the association of retinal microvascular measures with incident clinically relevant depressive symptoms are limited and findings are inconsistent (Geraets *et al.*, 2020; Ikram *et al.*, 2010; van Gennip *et al.*, 2022).

In a large population-based cohort, we investigated the association of retinal microvascular function, as measured by central retinal arteriolar equivalent or caliber and central retinal venular equivalent or caliber (CRAE and CRVE) and flicker light-induced retinal dilation, with incidence and trajectories of clinically relevant depressive symptoms.

Methods and materials

Study design

We used prospective data from The Maastricht Study, an observational population-based cohort study, the rationale and methodology of which have been described previously (Schram *et al.*, 2014). In brief, the study focuses on the etiology and pathophysiology of type 2 diabetes mellitus and the development of chronic diseases and is characterized by an extensive phenotyping approach. Eligible for participation were all individuals aged between 40 and 75 years and living in the southern part of the Netherlands. Participants were recruited through mass media campaigns and from the municipal registries and the regional Diabetes Patient Registry via mailings. Recruitment was stratified according to known type 2 diabetes status, with an oversampling of individuals with type 2 diabetes for reasons of efficiency. The present report includes prospective data from the first 7689 participants who completed the baseline survey between November 2010 and December 2017. The examinations of each participant were performed within a time window of 3 months. The study has been approved by the institutional medical ethical committee (NL31329.068.10) and the Dutch Minister of Health, Welfare and Sports (Permit 131088-105234-PG). All participants gave written informed consent. Data are available from The Maastricht Study for any researcher who meets the criteria for access to confidential data, and the corresponding author may be contacted to request data.

Retinal microvascular function

We quantified retinal microvascular function by retinal microvascular calibers (CRAE and CRVE) and flicker light-induced retinal dilation. Protocols of these measurements have been described previously (Li *et al.*, 2020).

Retinal microvascular calibers

Fundus photography was performed using an auto-focus, shot and tracker 45° camera (Model AFC-230; Nidek) in an optic disc-centered field of view, as described previously (Li *et al.*, 2020). The six largest arterioles and venules passing through an area one-half to one disc diameter from the optic margin were measured and summarized as CRAE and CRVE using RHINO software (Eindhoven University of Technology, Eindhoven, the Netherlands) (Li *et al.*, 2020). Calibers were obtained in both eyes from 2013 onward; data on both eyes were available in 53.8% out of the 7689 participants. When data on two eyes were available, we used the average of CRAE and CRVE of both eyes.

Flicker light-induced retinal dilation

We measured retinal arteriolar and venular dilation to flicker light exposure by the Dynamic Vessel Analyzer (Imedos, Jena, Germany), as described previously (Li *et al.*, 2020). Investigation of the left or right eye was randomly chosen. A 50 s baseline recording was followed by 40 s flicker light exposure and a subsequent 60 s recovery period. We calculated baseline diameters (in measurement units) as the average diameter during the 20–50 s recording. We calculated absolute arteriolar and venular dilation over baseline using the maximal dilation achieved at time points of 10 and 40 s during the flicker stimulation period, as done previously (van der Heide *et al.*, 2023).

Clinically relevant depressive symptoms

Depressive symptoms were assessed at baseline and annually during follow-up using the 9-item Patient Health Questionnaire (PHQ-9) (Kroenke, Spitzer, & Williams, 2001). The PHQ-9 is a self-administered questionnaire and is based on the Diagnostic and Statistical Manual of Mental Disorders 4th edition criteria for a major depressive episode. Each item is scored from 0 to 3, with a higher score representing more depressive symptoms. Clinically relevant depressive symptoms were defined as a pre-defined PHQ-9 cut-off score of ≥ 10 (Kroenke *et al.*, 2001). Current or lifetime major depression diagnosis was assessed solely at baseline using the Mini-International Neuropsychiatric Interview (Sheehan *et al.*, 1998). Online Supplementary Methods S1 provides a detailed definition of major depression.

Covariates

Covariates were assessed at the baseline examination. We assessed education level, smoking, alcohol use, dietary habits (Looman *et al.*, 2017; van der Heide *et al.*, 2021), and prior cardiovascular disease (CVD) by questionnaire. Physical activity was assessed by questionnaire and by accelerometry (Schram *et al.*, 2014). Glucose metabolism status, blood pressure, body mass index, waist circumference, lipid levels, and markers of low-grade inflammation were measured using standardized methods (Schram *et al.*, 2014). Online Supplementary Methods S2 provides further definitions of covariates.

Statistical analysis

All analyses were done on individuals free of clinically relevant depressive symptoms at baseline (baseline PHQ-9 score < 10). We excluded individuals with clinically relevant depressive

symptoms at baseline to limit the possibility of reverse causation (VanderWeele, 2021; VanderWeele, Jackson, & Li, 2016). We evaluated the association between retinal microvascular function, as measured by CRAE and CRVE and flicker light-induced retinal dilation, with incidence and trajectories of clinically relevant depressive symptoms. Prior studies have reported that both larger (Heringa et al., 2013; McGeechan et al., 2009; McGrory et al., 2017) and smaller (Heringa et al., 2013; McGeechan et al., 2009; McGrory et al., 2017) CRAE are associated with higher prevalence of features of cerebral small vessel disease and higher dementia risk. We therefore did not inverse CRAE values. CRAE and CRVE were expressed per standard deviation (s.d.). We inverted flicker light-induced retinal arteriolar and venular dilation so that higher values indicate worse microvascular function. We calculated a composite score for the flicker light-induced retinal arteriolar and venular dilation, as done previously (van der Heide et al., 2023). The composite score was calculated as the standardized average of the *z*-scores of flicker light-induced retinal arteriolar and venular dilations.

To calculate trajectories of clinically relevant depressive symptoms, we used a group-based trajectory modeling approach, which is based on finite mixture modeling (i.e. latent class growth modeling). This analysis was done with Stata software version 17 (StataCorp) using the *traj*-command (Jones & Nagin, 2013). An example of the code used is provided in online Supplementary Methods S3. This analysis aims to capture the heterogeneity in the population by identifying subgroups with comparable presence of clinically relevant depressive symptoms over time. Individuals are allocated to one trajectory based on their highest posterior probability (Nagin & Odgers, 2010). We estimated the number of distinct trajectories based on model fit statistics (Bayesian information criterion and average posterior probabilities) and clinical interpretation while maintaining ≥ 100 participants in each trajectory (Nagin & Odgers, 2010).

We used Cox regression with time-in-study as the time scale to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) for the association between a larger CRAE and CRVE and a lower flicker light-induced retinal dilation composite score with incident clinically relevant depressive symptoms. Follow-up time was calculated from baseline (2010–2017) to incidence of clinically relevant depressive symptoms or time of the last examination, whichever came first. The proportional hazard assumption was assessed using Schoenfeld's test. In addition, we used multinomial logistic regression to estimate odds ratios (ORs) and 95% CIs for the association between a larger CRAE and CRVE and a lower flicker light-induced retinal dilation composite score with probability of belonging to one of the trajectories of clinically relevant depressive symptoms. All analyses were adjusted for the following potential confounders: age, sex, education, and glucose metabolism status (model 1), and for body mass index, smoking, alcohol use, total-to-high-density lipoprotein cholesterol ratio, lipid-modifying medication use, dietary habits, and moderate-to-vigorous physical activity (model 2), and for prior CVD, systolic blood pressure, and antihypertensive medication use (model 3), and for baseline PHQ-9 scores (model 4) (Empana et al., 2021; Vaccarino et al., 2020). Conclusions were based on model 4.

We imputed data on covariates using multiple imputation by chained equations under the assumption that data were missing at random (Heymans & Eekhout, 2019). We used predictive mean matching to impute 20 datasets with each 10 iterations. We pooled results across all imputed datasets using the Rubin's rule (Heymans & Eekhout, 2019).

We did several additional analyses. First, we tested interaction with age, sex, glucose metabolism status, or systolic blood pressure (Stehouwer, 2018). Second, we repeated the analysis with the individual flicker light-induced retinal arteriolar and venular dilation. Third, analyses were repeated after excluding individuals who had a major depression diagnosis at baseline (i.e. individuals without clinically relevant depressive symptoms can have a major depression diagnosis, online Supplementary Methods S1), used antidepressant medication at baseline, or had a lifetime history of depression. Fourth, we adjusted for income instead of education, for mean 24 h instead of office systolic blood pressure, for waist circumference instead of body mass index, and for moderate-to-vigorous physical activity assessed by accelerometry instead of by questionnaire. Fifth, we additionally adjusted for markers of low-grade inflammation. We did not adjust for low-grade inflammation in the main analysis, because low-grade inflammation may act as a confounder, antecedent, or mediator (Aizenstein et al., 2016). Sixth, we repeated the analysis with flicker light-induced retinal arteriolar and venular dilation expressed as percentage dilation over baseline based on the average dilation achieved at time points of 10 and 40 s to account for interindividual variation in the curve shape during dilation (Li et al., 2020). Seventh, we mutually adjusted for CRVE and CRAE, to explore if associations of CRAE and CRVE are linked. Eighth, we conducted a complete case analysis without imputation for covariates. Finally, to explore if retinal microvascular function mediates the association between prior CVD and incident clinically relevant depressive symptoms (if any), we evaluated the association between prior CVD and incident clinically relevant depressive symptoms with and without adjustment for the retinal microvascular measures.

Results

Online Supplementary Fig. S1 shows the flowchart for the derivation of the study population. The study population included 5952 individuals free of clinically relevant depressive symptoms at baseline who had complete data on CRAE and CRVE and data on depressive symptoms on at least one follow-up examination. Flicker light-induced retinal dilation was available in a subsample of 4744 individuals (online Supplementary Fig. S1). Characteristics of the subpopulation with data on flicker light-induced retinal dilation were comparable with the total study population (online Supplementary Table S1). Mean age of the total study population was 59.9 (s.d.: 8.5) years and 49.7% were women (Table 1). The individuals excluded due to missing data ($n = 1408$) or clinically relevant depressive symptoms at baseline ($n = 292$) were less educated and had a worse cardiovascular risk profile compared to those included (online Supplementary Table S2).

Incident clinically relevant depressive symptoms

During a median follow-up of 7.0 (range: 1.0–11.0) years, 806 (13.5%) individuals had incident clinically relevant depressive symptoms on at least one of the follow-up examinations. Results of the Cox regression showed that one s.d. larger CRAE (19.7 μm) and one s.d. larger CRVE (30.1 μm) were each associated with a lower risk of clinically relevant depressive symptoms (HR: 0.89 [95% CI 0.83–0.96] and 0.93 [0.86–0.99], respectively) (Fig. 1). In addition, one s.d. lower flicker light-induced retinal dilation composite score was associated with a higher risk of clinically relevant depressive symptoms (HR: 1.10 [1.01–1.20]) (Fig. 1).

Table 1. Characteristics of the total study population on retinal microvascular calibers, and according to incidence and trajectories of clinically relevant depressive symptoms

	Total study population (n = 5952)	Incidence of clinically relevant depressive symptoms ^a		Trajectories ^b of clinically relevant depressive symptoms ^a			
		No incident depressive symptoms (n = 5146, 86.5%)	Incident depressive symptoms (n = 806, 13.5%)	Low (n = 5225, 87.8%)	Early-chronic (n = 157, 2.6%)	Late-increasing (n = 247, 4.2%)	Remitting (n = 323, 5.4%)
<i>Demography</i>							
Age, years	59.9 (8.5)	59.9 (8.5)	59.8 (8.9)	59.9 (8.5)	59.8 (8.1)	60.8 (9.3)	59.3 (9.0)
Sex							
Female, No (%)	2960 (49.7)	2537 (49.3)	423 (42.5)	2578 (49.4)	83 (52.9)	128 (51.8)	171 (52.9)
Male, No (%)	2992 (50.3)	2609 (50.7)	383 (57.5)	2647 (50.6)	74 (47.1)	119 (48.2)	152 (47.1)
Education ^c							
Low, No (%)	1938 (33.0)	1608 (31.6)	330 (41.6)	1637 (31.7)	68 (43.9)	97 (39.9)	136 (42.8)
Intermediate, No (%)	1633 (27.8)	1415 (27.8)	218 (27.5)	1437 (27.8)	40 (25.8)	72 (29.6)	84 (26.4)
High, No (%)	2308 (39.3)	2063 (40.6)	245 (30.9)	2089 (40.5)	47 (30.3)	74 (30.5)	98 (30.8)
<i>Lifestyle variables</i>							
Smoking status ^d							
Never, No (%)	2249 (38.0)	1985 (38.8)	264 (32.9)	2018 (38.9)	47 (29.9)	81 (33.2)	103 (32.0)
Former, No (%)	2969 (50.2)	2574 (50.3)	395 (49.3)	2608 (50.2)	76 (48.4)	122 (50.0)	163 (50.6)
Current, No (%)	697 (11.8)	555 (10.9)	142 (17.7)	566 (10.9)	34 (21.7)	41 (16.8)	56 (17.4)
Alcohol use ^d							
None, No (%)	990 (16.7)	789 (15.4)	201 (25.1)	805 (15.5)	45 (28.7)	58 (23.8)	82 (25.6)
Low, No (%)	3618 (59.5)	3082 (60.3)	436 (54.5)	3128 (60.2)	72 (45.9)	138 (56.6)	180 (56.1)
High, No (%)	1407 (23.8)	1244 (24.3)	163 (20.4)	1260 (24.3)	40 (25.5)	48 (19.7)	59 (18.4)
Dutch Healthy Diet sum score ^e	84.3 (15.0)	84.7 (14.9)	81.4 (15.7)	84.7 (14.9)	80.5 (16.0)	81.7 (16.5)	81.8 (15.1)
Moderate-to-vigorous physical activity ^f , min/week	285 (180–480)	285 (180–480)	225 (105–420)	285 (180–480)	180 (90–405)	225 (98–420)	225 (135–480)
<i>Clinical characteristics</i>							
Glucose metabolism status							
Normal glucose metabolism, No (%)	3723 (62.6)	3294 (64.0)	429 (53.2)	3337 (63.9)	71 (45.2)	129 (52.2)	186 (57.6)
Prediabetes, No (%)	894 (15.0)	772 (15.0)	122 (15.1)	784 (15.0)	21 (13.4)	44 (17.8)	45 (13.9)
Type 2 diabetes, No (%)	1335 (22.4)	1080 (21.0)	255 (31.6)	1104 (21.1)	65 (41.4)	74 (30.0)	92 (28.5)
Hypertension ^g , No (%)	3147 (52.9)	2664 (51.8)	483 (59.9)	2714 (52.0)	98 (62.4)	145 (58.7)	190 (58.8)
Prior CVD ^h , No (%)	960 (16.3)	796 (15.6)	164 (20.6)	809 (15.6)	34 (21.8)	42 (17.4)	75 (23.5)
Body mass index ⁱ , kg/m ²	26.8 (4.4)	26.6 (4.2)	28.0 (5.2)	26.6 (4.2)	29.0 (5.7)	27.6 (5.3)	27.9 (4.9)

Systolic blood pressure ^e , mmHg	133.4 (17.7)	133.3 (17.7)	133.9 (17.6)	133.3 (17.7)	135.7 (17.0)	132.5 (16.5)	133.8 (18.9)
Diastolic blood pressure ^k , mmHg	75.5 (9.7)	75.4 (9.6)	75.9 (10.2)	75.4 (9.7)	77.8 (9.9)	74.2 (9.7)	76.0 (10.5)
Total-to-HDL cholesterol ratio ^k	3.6 (1.2)	3.6 (1.2)	3.6 (1.2)	3.6 (1.1)	3.8 (1.3)	3.6 (1.1)	3.6 (1.1)
Lipid-modifying medication ^l , No (%)	1818 (30.6)	1524 (29.6)	294 (36.5)	1553 (29.8)	63 (40.1)	93 (37.7)	109 (33.8)
Antihypertensive medication ^l , No (%)	2178 (36.6)	1811 (35.2)	367 (45.5)	1844 (35.3)	84 (53.5)	115 (46.6)	135 (41.8)
<i>Retinal microvascular measures</i>							
CRAE, μm	138.1 (19.7)	138.2 (19.7)	137.5 (19.6)	138.2 (19.7)	136.3 (20.1)	137.9 (18.8)	137.8 (20.7)
CRVE, μm	208.7 (30.1)	208.6 (30.0)	209.2 (30.6)	208.5 (29.9)	209.6 (31.5)	209.2 (31.6)	209.6 (30.3)
Flicker light-induced arteriolar dilation, measurement unit	4.39 (3.75)	4.44 (3.75)	4.07 (3.77)	4.44 (3.74)	3.99 (3.95)	4.48 (4.14)	3.75 (3.48)
Flicker light-induced venular dilation, measurement unit	7.51 (4.17)	7.53 (4.20)	7.39 (4.00)	7.52 (4.19)	8.01 (4.16)	7.42 (4.04)	7.20 (4.08)
Composite score of flicker light-induced retinal dilation, s.d.	0.00 (1.00)	-0.02 (1.00)	0.08 (0.98)	-0.01 (0.99)	0.00 (1.04)	0.01 (1.04)	0.17 (0.94)
Baseline PHQ-9 score	2 (0-4)	1 (0-3)	4 (2-7)	1 (0-3)	6 (4-8)	4 (2-6)	4 (2-6)

Data are means (s.d.) or median (interquartile range).

CVD, cardiovascular disease; HDL, high-density lipoprotein; PHQ-9, 9-item Patient Health Questionnaire; CRAE, central retinal arteriolar equivalent or caliber; CRVE, central retinal venular equivalent or caliber.

^aClinically relevant depressive symptoms were defined as a PHQ-9 score of ≥ 10 .

^bTrajectories of clinically relevant depressive symptoms are defined in Fig. 2.

^cData available in $n = 5879$.

^dData available in $n = 5915$.

^eData available in $n = 5709$.

^fData available in $n = 5332$.

^gData available in $n = 5945$.

^hData available in $n = 5894$.

ⁱData available in $n = 5983$.

^jData available in $n = 5950$.

^kData available in $n = 5949$.

^lData available in $n = 5948$.




Figure 1. Association between CRAE, CRVE, and the composite score of flicker light-induced retinal dilation and incident clinically relevant depressive symptoms (PHQ-9 score ≥ 10). Results are reported for CRAE and CRVE expressed per one larger s.d. and for the composite score of flicker light-induced retinal dilation per one lower s.d. Model 1 adjusted for age, sex, education, and glucose metabolism status. Model 2 additionally adjusted for body mass index, smoking, alcohol use, total/HDL ratio, lipid-modifying medication use, dietary habits, and moderate-to-vigorous physical activity. Model 3 additionally adjusted for prior CVD, systolic blood pressure, and antihypertensive medication use. Model 4 additionally adjusted for baseline PHQ-9 score. CRAE, central retinal arteriolar equivalent or caliber; CRVE, central retinal venular equivalent or caliber; s.d., standard deviation; PHQ-9, 9-item Patient Health Questionnaire; HDL, high-density lipoprotein; CVD, cardiovascular disease.

Trajectories of clinically relevant depressive symptoms

We identified four trajectories defined by the presence of clinically relevant depressive symptoms (Fig. 2): (1) maintaining a low prevalence throughout the follow-up (low trajectory, $n = 5225$ [87.8%]); (2) increasing prevalence, then a chronic high prevalence (early-chronic trajectory, $n = 157$ [2.6%]); (3) a low prevalence, then increasing (late-increasing trajectory, $n = 247$ [4.2%]); and (4) increasing prevalence, then remitting (remitting trajectory, $n = 323$ [5.4%]). Online Supplementary Fig. S2 shows the median PHQ-9 scores by wave and online Supplementary Table S3 shows the fit statistics for the model selection and the polynomial used for each trajectory. The model we selected used a first-order




Figure 2. Trajectories of clinically relevant depressive symptoms (PHQ-9 score ≥ 10). The four trajectories are characterized by: (1) maintaining a low prevalence of clinically relevant depressive symptoms throughout the follow-up (low, purple, $n = 5225$ [87.8%]); (2) increasing prevalence of clinically relevant depressive symptoms and then maintaining a high prevalence (early-chronic, orange, $n = 157$ [2.6%]); (3) a low prevalence of clinically relevant depressive symptoms and then increasing (late-increasing, blue, $n = 247$ [4.2%]); and (4) increasing prevalence of clinically relevant depressive symptoms then remitting (remitting, green, $n = 323$ [5.4%]). Dashed lines are 95% CIs on the estimated trajectories. PHQ-9, 9-item Patient Health Questionnaire.

polynomial for the late-increasing trajectory and second-order polynomials for the other three trajectories, i.e. the low trajectory, the early-chronic trajectory, and the remitting trajectory (online Supplementary Table S3). The baseline characteristics according to the trajectories are shown in Table 1 and online Supplementary Table S2. Results of the multinomial regression showed that, using the low trajectory as the reference, one s.d. larger CRAE was associated with a lower odds of belonging to the early-chronic trajectory (OR: 0.83 [0.69–0.99]), but not with any of the other trajectories (Table 2). CRVE was not associated with any of the trajectories (Table 2). One s.d. lower flicker light-induced retinal dilation composite score was associated with a higher odds of belonging to the remitting trajectory (OR: 1.23 [1.07–1.43]), but not with any of the other trajectories (Table 2).

Additional analyses

There were no consistent interactions with age, sex, glucose metabolism status, or systolic blood pressure (online Supplementary Tables S4 and S5). Of the individual arteriolar and venular flicker light-induced dilation measures, a lower arteriolar dilation, but not venular dilation, was associated with a higher risk of clinically depressive symptoms and a higher odds of belonging to the remitting trajectory (online Supplementary Fig. S3 and Table S6). All other additional analyses provided results similar to those obtained in the main analysis (online Supplementary Tables S7 and S8). We did not observe mediating effects by the retinal microvascular measures of the association between prior CVD and incident clinically relevant depressive symptoms (online Supplementary Table S9).

Discussion

In this study, a larger CRAE and a larger CRVE were each associated with a lower risk of clinically relevant depressive symptoms, while a lower flicker light-induced retinal dilation was associated

Table 2. Association between CRAE and CRVE and the composite score of flicker light-induced retinal dilation and trajectories of clinically relevant depressive symptoms^a (PHQ-9 score ≥ 10)

	Retinal microvascular calibers			Composite score of flicker light-induced retinal dilation (s.d.)	
		CRAE (s.d.)	CRVE (s.d.)		
	<i>n</i>	OR (95% CI)		<i>n</i>	OR (95% CI)
Trajectories		Model 1			Model 1
Low	5225	Reference	Reference	4185	Reference
Early-chronic	157	0.87 (0.74–1.02)	1.00 (0.86–1.18)	121	1.00 (0.83–1.21)
Late-increasing	247	0.98 (0.86–1.12)	1.02 (0.90–1.16)	189	1.00 (0.86–1.16)
Remitting	323	0.94 (0.84–1.05)	1.01 (0.90–1.13)	249	1.25 (1.09–1.45)
		Model 2			Model 2
Low	5225	Reference	Reference	4185	Reference
Early-chronic	157	0.85 (0.73–1.01)	0.96 (0.81–1.12)	121	1.01 (0.84–1.21)
Late-increasing	247	0.97 (0.85–1.10)	1.00 (0.88–1.13)	189	0.99 (0.86–1.15)
Remitting	323	0.93 (0.83–1.04)	0.98 (0.87–1.10)	249	1.26 (1.09–1.46)
		Model 3			Model 3
Low	5225	Reference	Reference	4185	Reference
Early-chronic	157	0.86 (0.73–1.02)	0.96 (0.82–1.13)	121	1.00 (0.83–1.20)
Late-increasing	247	0.96 (0.84–1.09)	0.99 (0.87–1.13)	189	0.99 (0.86–1.15)
Remitting	323	0.93 (0.83–1.05)	0.98 (0.88–1.10)	249	1.25 (1.08–1.44)
		Model 4			Model 4
Low	5225	Reference	Reference	4185	Reference
Early-chronic	157	0.83 (0.69–0.99)	0.92 (0.77–1.09)	121	0.99 (0.82–1.21)
Late-increasing	247	0.94 (0.82–1.08)	0.98 (0.86–1.12)	189	0.98 (0.84–1.13)
Remitting	323	0.92 (0.81–1.04)	0.97 (0.86–1.09)	249	1.23 (1.07–1.43)

Results are reported for CRAE and CRVE expressed per one larger s.d. and for the composite score of flicker light-induced retinal dilation per one lower s.d. Model 1 adjusted for age, sex, education, and glucose metabolism status. Model 2 additionally adjusted for body mass index, smoking, alcohol use, total/HDL ratio, lipid-modifying medication use, dietary habits, and moderate-to-vigorous physical activity. Model 3 additionally adjusted for prior CVD, systolic blood pressure, and antihypertensive medication use. Model 4 additionally adjusted for baseline PHQ-9 score.

CRAE, central retinal arteriolar equivalent or caliber; CRVE, central retinal venular equivalent or caliber; s.d., standard deviation; PHQ-9, 9-item Patient Health Questionnaire; HDL, high-density lipoprotein; CVD, cardiovascular disease.

^aGraphical representation of trajectories of clinically relevant depressive symptoms is shown in Fig. 2.

with a higher risk of clinically relevant depressive symptoms. The trajectory analyses showed that a larger CRAE was associated with a lower odds of belonging to the early-chronic trajectory, and a lower flicker light-induced retinal dilation with a higher odds of belonging to the remitting trajectory.

Three population-based studies (Geraets et al., 2020; Ikram et al., 2010; van Gennip et al., 2022) have evaluated the association between retinal microvascular function and incident clinically relevant depressive symptoms. Data on the association between CRAE and CRVE and incident clinically relevant depressive symptoms have been inconsistent. The Multi-Ethnic Study of Atherosclerosis (MESA) found that a larger CRVE, but not CRAE, was associated with a higher risk of clinically relevant depressive symptoms (van Gennip et al., 2022), whereas The Rotterdam Study found that CRAE and CRVE were not associated with incident clinically relevant depressive symptoms (Ikram et al., 2010). Our current findings are supported by results of an early analysis on flicker light-induced retinal dilation from The Maastricht Study (Geraets et al., 2020) in a restricted sample ($N = 1865$) with a maximum follow-up of 4 years. In that analysis,

a lower flicker light-induced retinal arteriolar dilation was associated with a higher risk of clinically relevant depressive symptoms, whereas a lower flicker light-induced venular dilation was not (Geraets et al., 2020). We extend these previous studies as the present study had a larger number of follow-up examinations (nine follow-up examinations *v.* three in MESA, van Gennip et al., 2022; two in The Rotterdam Study, Ikram et al., 2010; and four in the previous Maastricht Study analysis, Geraets et al., 2020) and a larger sample size ($n = 5952$ *v.* $n = 4336$ in MESA, van Gennip et al., 2022; $n = 3605$ in The Rotterdam Study, Ikram et al., 2010; and $n = 1865$ in the previous Maastricht Study analysis, Geraets et al., 2020) which allowed us to evaluate not only incidence but also trajectories of clinically relevant depressive symptoms.

The associations of larger CRAE and CRVE and lower flicker light-induced retinal dilation with risk of clinically depressive symptoms are consistent with the vascular depression hypothesis (Aizenstein et al., 2016). In general, the interpretation of CRAE and CRVE is complex, because both larger and smaller CRAE or CRVE may reflect microvascular dysfunction. Changes in

CRAE and CRVE might represent a dynamic process, and the interpretation might differ according to different stages of microvascular dysfunction (McGrory *et al.*, 2017). Widening of calibers might reflect early-stage microvascular dysfunction resulting from impaired autoregulation (Gardiner, Archer, Curtis, & Stitt, 2007), while narrowing of calibers might reflect late-stage microvascular dysfunction resulting from microvascular remodeling (McGrory *et al.*, 2017). In contrast to MESA (van Gennip *et al.*, 2022), in which larger CRVE was found to be associated with a higher risk of clinically relevant depressive symptoms, we found that larger CRVE was associated with a lower risk of clinically relevant depressive symptoms. These contrasting findings might be explained by different study populations. Participants in the present study had a more adverse cardiometabolic profile (e.g. prevalence of type 2 diabetes was 22.4% in our study [by design] *v.* 13.7% in MESA; and prior CVD was 16.3% in our study *v.* 0% [by design] in MESA). This worse cardiometabolic profile may be accompanied by a more advanced stage of microvascular dysfunction. Another explanation might be that a larger CRVE is associated with a lower risk of clinically relevant depressive symptoms because of confounding effects of CRAE. Venular dilatation might be a consequence of arteriolar dilatation possibly due to higher transmission of blood pressure (Gardiner *et al.*, 2007). In accordance, when we additionally adjusted the associations of CRVE for CRAE, the associations attenuated. However, the finding of this additional analysis needs to be interpreted with caution, because we cannot exclude the effects of multicollinearity between CRAE and CRVE (correlation between CRAE and CRVE in our study was 0.74) (Vatcheva, Lee, McCormick, & Rahbar, 2016). A lower retinal dilation after flicker light exposure is thought to reflect impaired neurovascular coupling, a mechanism that can rapidly increase blood flow to activated regions (Empana *et al.*, 2021). Impaired neurovascular coupling can result in perfusion deficits, which may contribute to clinically relevant depressive symptoms (Empana *et al.*, 2021).

The trajectory analyses suggest that CRAE may correlate more closely with a chronic disease course, whereas altered flicker light-induced retinal dilation may correlate with clinically relevant depressive symptoms that can remit over time. Possibly, arteriolar narrowing may reflect more structural and less reversible changes in the retinal microvasculature (Houben, Martens, & Stehouwer, 2017), and CRAE may, thus, correlate more closely with a chronic disease course. In contrast, altered flicker light-induced retinal dilation may reflect a more functional and easily reversible change (Houben *et al.*, 2017), and, thus, correlate with clinically relevant depressive symptoms that can remit over time. However, this study is the first to investigate the association of microvascular dysfunction with trajectories of clinically relevant depressive symptoms, and this issue requires further study.

From a clinical point of view, this study suggests that cerebral microvascular dysfunction could be a target for prevention, treatment, and prediction of depression. Evidence suggests that both lifestyle modifications, such as weight loss and physical activity, and drugs, such as phosphodiesterase-3 inhibitors (cilostazol), nitric oxide donors (isosorbide mononitrate), and some antihyperglycemic agents (metformin and glucagon-like peptide-1 receptor agonist), may improve microvascular function and have antidepressant effects (Empana *et al.*, 2021). Furthermore, retinal microvascular measures might help to identify individuals who will most likely benefit from targeted prevention for depression.

Depressive symptoms frequently co-occur with other cerebral syndromes or diseases, including dementia, cognitive dysfunction

(Empana *et al.*, 2021), and other mental illness, such as anxiety (Tanaka & Chen, 2023). It has been suggested that this link may be explained partially by microvascular dysfunction as a common underlying cause (Empana *et al.*, 2021; Mirza *et al.*, 2016; Singh-Manoux *et al.*, 2017). This hypothesis is supported by our current findings and by findings of The Rotterdam Study showing that changes in retinal microvascular calibers (i.e. larger CRVE, but not CRAE) were associated with a higher risk of dementia (de Jong *et al.*, 2011). In contrast, The Atherosclerosis Risk in Communities study found that CRAE and CRVE were not associated with cognitive decline (Lesage *et al.*, 2009). The association of retinal microvascular function with anxiety has not yet been investigated.

This study has several limitations. First, depressive symptoms were assessed by questionnaire, and antidepressant medication use was assessed solely at baseline. In addition, we did not analyze depressive symptoms on a continuous scale, which may have reduced our statistical power. Second, the study population consisted mostly of White individuals, and the results may therefore not generalize to other ethnic groups. The results of our trajectory analysis need to be interpreted in light of its own limitations. First, a limitation of trajectory analysis involves the complexity and flexibility of its data-driven models (Twisk & Hoekstra, 2012). The number of trajectories and their characteristics are influenced by statistical procedure used for the trajectory selection (Twisk & Hoekstra, 2012), the study population and the number of follow-up examinations (Nagin & Tremblay, 2001). Therefore, our results on trajectories of clinically relevant depressive symptoms require replication in other cohorts. Second, it is important to acknowledge that trajectory allocation based on posterior probabilities may lead to uncertainty in the trajectory assignment. Third, latent class growth modeling (i.e. group-based trajectory modeling) defines trajectories under the assumption that there is no variation within trajectories (Herle *et al.*, 2020). Latent class growth mixture modeling is an extension of latent class growth modeling that may lead to a better model fit because it allows individuals to differ in trajectory within groups. However, this approach is more complex and sometimes leads to models that do not converge (Twisk & Hoekstra, 2012). Future research is required to investigate which approach performs best.

In conclusion, larger CRAE and larger CRVE were each associated with a lower risk of clinically relevant depressive symptoms, and a larger CRAE with a lower odds of belonging to the early-chronic trajectory. Furthermore, a lower flicker light-induced retinal dilation was associated with a higher risk of clinically relevant depressive symptoms and a higher odds of belonging to the remitting trajectory. These findings support the hypothesis that cerebral microvascular dysfunction contributes to the development of depressive symptoms. In addition, these findings suggest that CRAE may correlate more closely with a chronic disease course, whereas altered flicker light-induced retinal dilation may correlate with clinically relevant depressive symptoms that can remit over time.

Supplementary material. The supplementary material for this article can be found at <https://doi.org/10.1017/S0033291724000618>.

Funding statement. The Maastricht Study was supported by the European Regional Development Fund via OP-Zuid (31O.041), the Province of Limburg, the Dutch Ministry of Economic Affairs (31O.041), Stichting De Weijerhorst, the Pearl String Initiative Diabetes, CVC Maastricht, Imedos Health GmbH, CARIM Maastricht, CAPHRI Maastricht, NUTRIM Maastricht, Stichting Annadal, Health Foundation Limburg, Netherlands Organization for Health Research and Development (ZonMW), Netherlands

Consortium of Dementia Cohorts, and the Memorabel program. In addition, this work was supported by the Netherlands Organization for Health Research and Development (ZonMW) Veni research grant (TVS, grant number 916.19.074), a Diabetes Fonds Junior Fellowship grant (TVS grant number 2021.81.004), and by a Dutch Heart Foundation research grant (AVG, TVS grant number 2018T025).

Competing interests. None.

Ethical standards. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human subjects were approved by the institutional medical ethical committee (NL31329.068.10) and the Minister of Health, Welfare, and Sports of the Netherlands (Permit 131088-105234-PG).

References

- Aizenstein, H. J., Baskys, A., Boldrini, M., Butters, M. A., Diniz, B. S., Jaiswal, M. K., ... Tene, O. (2016). Vascular depression consensus report – A critical update. *BMC Medicine*, *14*(1), 161. doi:10.1186/s12916-016-0720-5
- Cheung, C. Y., Chan, V. T. T., Mok, V. C., Chen, C., & Wong, T. Y. (2019). Potential retinal biomarkers for dementia: What is new? *Current Opinion in Neurology*, *32*(1), 82–91. doi:10.1097/WCO.0000000000000645
- Cheung, C. Y., Ikram, M. K., Chen, C., & Wong, T. Y. (2017). Imaging retina to study dementia and stroke. *Progress in Retinal Eye Research*, *57*, 89–107. doi:10.1016/j.preteyeres.2017.01.001
- de Jong, F. J., Schrijvers, E. M., Ikram, M. K., Koudstaal, P. J., de Jong, P. T., Hofman, A., ... Breteler, M. M. (2011). Retinal vascular caliber and risk of dementia: The Rotterdam Study. *Neurology*, *76*(9), 816–821. doi:10.1212/WNL.0b013e31820e7baa
- Direk, N., Koudstaal, P. J., Hofman, A., Ikram, M. A., Hoogendijk, W. J., & Tiemeier, H. (2012). Cerebral hemodynamics and incident depression: The Rotterdam Study. *Biological Psychiatry*, *72*(4), 318–323. doi:10.1016/j.biopsych.2012.01.019
- Empaña, J. P., Boutouyrie, P., Lemogne, C., Jouven, X., & van Sloten, T. T. (2021). Microvascular contribution to late-onset depression: Mechanisms, current evidence, association with other brain diseases, and therapeutic perspectives. *Biological Psychiatry*, *90*(4), 214–225. doi:10.1016/j.biopsych.2021.04.012
- Gardiner, T. A., Archer, D. B., Curtis, T. M., & Stitt, A. W. (2007). Arteriolar involvement in the microvascular lesions of diabetic retinopathy: Implications for pathogenesis. *Microcirculation (New York, N.Y.: 1994)*, *14*(1), 25–38. doi:10.1080/10739680601072123
- Geraets, A. F. J., van Agtmaal, M. J. M., Stehouwer, C. D. A., Sorensen, B. M., Berendschot, T., Webers, C. A. B., ... Houben, A. (2020). Association of markers of microvascular dysfunction with prevalent and incident depressive symptoms: The Maastricht Study. *Hypertension*, *76*(2), 342–349. doi:10.1161/HYPERTENSIONAHA.120.15260
- Heringa, S. M., Bouvy, W. H., van den Berg, E., Moll, A. C., Kappelle, L. J., & Biessels, G. J. (2013). Associations between retinal microvascular changes and dementia, cognitive functioning, and brain imaging abnormalities: A systematic review. *Journal of Cerebral Blood Flow & Metabolism*, *33*(7), 983–995. doi:10.1038/jcbfm.2013.58
- Herle, M., Micali, N., Abdulkadir, M., Loos, R., Bryant-Waugh, R., Hubel, C., ... De Stavola, B. L. (2020). Identifying typical trajectories in longitudinal data: Modelling strategies and interpretations. *European Journal of Epidemiology*, *35*(3), 205–222. doi:10.1007/s10654-020-00615-6
- Heymans, M. W., & Eekhout, I. (2019). Applied missing data analysis with SPSS and (R)Studio. Heymans and Eekhout: Amsterdam. Retrieved from: <https://bookdown.org/mwheymans/bookmi/>.
- Houben, A., Martens, R. J. H., & Stehouwer, C. D. A. (2017). Assessing microvascular function in humans from a chronic disease perspective. *Journal of the American Society of Nephrology*, *28*(12), 3461–3472. doi:10.1681/ASN.2017020157
- Ikram, M. K., Luijckendijk, H. J., Hofman, A., de Jong, P. T., Breteler, M. M., Vingerling, J. R., & Tiemeier, H. (2010). Retinal vascular calibers and risk of late-life depression: The Rotterdam Study. *The American Journal of Geriatric Psychiatry*, *18*(5), 452–455. doi:10.1097/jgp.0b013e3181d69250
- Jones, B. L., & Nagin, D. S. (2013). A note on a Stata plugin for estimating group-based trajectory models. *Sociological Methods & Research*, *42*(4), 608–613. doi:10.1177/0049124113503141
- Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: Validity of a brief depression severity measure. *Journal of General Internal Medicine*, *16*(9), 606–613. doi:10.1046/j.1525-1497.2001.016009606.x
- Lesage, S. R., Mosley, T. H., Wong, T. Y., Szklo, M., Knopman, D., Catellier, D. J., ... Sharrett, A. R. (2009). Retinal microvascular abnormalities and cognitive decline: The ARIC 14-year follow-up study. *Neurology*, *73*(11), 862–868. doi:10.1212/WNL.0b013e3181b78436
- Li, W., Schram, M. T., Sorensen, B. M., Agtmaal, M. J. M., Berendschot, T., Webers, C. A. B., ... Houben, A. (2020). Microvascular phenotyping in the Maastricht Study: Design, and main findings, 2010–2018. *American Journal of Epidemiology*, *189*(9), 873–884. doi:10.1093/aje/kwaa023
- Looman, M., Feskens, E. J., de Rijk, M., Meijboom, S., Biesbroek, S., Temme, E. H., ... Geelen, A. (2017). Development and evaluation of the Dutch healthy diet index 2015. *Public Health Nutrition*, *20*(13), 2289–2299. doi:10.1017/S136898001700091X
- McGeechan, K., Liew, G., Macaskill, P., Irwig, L., Klein, R., Klein, B. E., ... Wong, T. Y. (2009). Prediction of incident stroke events based on retinal vessel caliber: A systematic review and individual-participant meta-analysis. *American Journal of Epidemiology*, *170*(11), 1323–1332. doi:10.1093/aje/kwp306
- McGrory, S., Cameron, J. R., Pellegrini, E., Warren, C., Doubal, F. N., Deary, I. J., ... MacGillivray, T. J. (2017). The application of retinal fundus camera imaging in dementia: A systematic review. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*, *6*, 91–107. doi:10.1016/j.dadm.2016.11.001
- Mirza, S. S., Wolters, F. J., Swanson, S. A., Koudstaal, P. J., Hofman, A., Tiemeier, H., & Ikram, M. A. (2016). 10-Year trajectories of depressive symptoms and risk of dementia: A population-based study. *The Lancet. Psychiatry*, *3*(7), 628–635. doi:10.1016/S2215-0366(16)00097-3
- Musliner, K. L., Munk-Olsen, T., Eaton, W. W., & Zandi, P. P. (2016). Heterogeneity in long-term trajectories of depressive symptoms: Patterns, predictors and outcomes. *Journal of Affective Disorders*, *192*, 199–211. doi:10.1016/j.jad.2015.12.030
- Nagin, D. S., & Odgers, C. L. (2010). Group-based trajectory modeling in clinical research. *Annual Review of Clinical Psychology*, *6*, 109–138. doi:10.1146/annurev.clinpsy.121208.131413
- Nagin, D. S., & Tremblay, R. E. (2001). Analyzing developmental trajectories of distinct but related behaviors: A group-based method. *Psychological Methods*, *6*(1), 18–34. doi:10.1037/1082-989x.6.1.18
- Rensma, S. P., van Sloten, T. T., Launer, L. J., & Stehouwer, C. D. A. (2018). Cerebral small vessel disease and risk of incident stroke, dementia and depression, and all-cause mortality: A systematic review and meta-analysis. *Neuroscience Biobehavioral Reviews*, *90*, 164–173. doi:10.1016/j.neubiorev.2018.04.003
- Schram, M. T., Sep, S. J., van der Kallen, C. J., Dagnelie, P. C., Koster, A., Schaper, N., ... Stehouwer, C. D. (2014). The Maastricht Study: An extensive phenotyping study on determinants of type 2 diabetes, its complications and its comorbidities. *European Journal of Epidemiology*, *29*(6), 439–451. doi:10.1007/s10654-014-9889-0
- Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., ... Dunbar, G. C. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *Journal of Clinical Psychiatry*, *59*(Suppl 20), 22–33; quiz 34–57. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9881538>
- Singh-Manoux, A., Dugravot, A., Fournier, A., Abell, J., Ebmeier, K., Kivimaki, M., & Sabia, S. (2017). Trajectories of depressive symptoms before diagnosis of dementia: A 28-year follow-up study. *JAMA Psychiatry*, *74*(7), 712–718. doi:10.1001/jamapsychiatry.2017.0660
- Stehouwer, C. D. A. (2018). Microvascular dysfunction and hyperglycemia: A vicious cycle with widespread consequences. *Diabetes*, *67*(9), 1729–1741. doi:10.2337/dbi17-0044

- Tanaka, M., & Chen, C. (2023). Editorial: Towards a mechanistic understanding of depression, anxiety, and their comorbidity: Perspectives from cognitive neuroscience. *Frontiers in Behavioral Neuroscience*, *17*, 1268156. doi:10.3389/fnbeh.2023.1268156
- Twisk, J., & Hoekstra, T. (2012). Classifying developmental trajectories over time should be done with great caution: A comparison between methods. *Journal of Clinical Epidemiology*, *65*(10), 1078–1087. doi:10.1016/j.jclinepi.2012.04.010
- Umemura, T., Kawamura, T., & Hotta, N. (2017). Pathogenesis and neuroimaging of cerebral large and small vessel disease in type 2 diabetes: A possible link between cerebral and retinal microvascular abnormalities. *Journal of Diabetes Investigation*, *8*(2), 134–148. doi:10.1111/jdi.12545
- Vaccarino, V., Badimon, L., Bremner, J. D., Cenko, E., Cubedo, J., Dorobantu, M., ... Reviewers, E. S. C. S. D. G. (2020). Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. *European Heart Journal*, *41*(17), 1687–1696. doi:10.1093/eurheartj/ehy913
- van Agtmaal, M. J. M., Houben, A., Pouwer, F., Stehouwer, C. D. A., & Schram, M. T. (2017). Association of microvascular dysfunction with late-life depression: A systematic review and meta-analysis. *JAMA Psychiatry*, *74*(7), 729–739. doi:10.1001/jamapsychiatry.2017.0984
- van der Heide, F. C. T., Eussen, S., Houben, A., Henry, R. M. A., Kroon, A. A., van der Kallen, C. J. H., ... Stehouwer, C. D. A. (2023). Alcohol consumption and microvascular dysfunction: A J-shaped association: The Maastricht Study. *Cardiovascular Diabetology*, *22*(1), 67. doi:10.1186/s12933-023-01783-x
- van der Heide, F. C. T., Steens, I. L. M., Geraets, A. F. J., Foreman, Y. D., Henry, R. M. A., Kroon, A. A., ... Stehouwer, C. D. A. (2021). Association of retinal nerve fiber layer thickness, an index of neurodegeneration, with depressive symptoms over time. *JAMA Network Open*, *4*(11), e2134753. doi:10.1001/jamanetworkopen.2021.34753
- VanderWeele, T. J. (2021). Can sophisticated study designs with regression analyses of observational data provide causal inferences? *JAMA Psychiatry*, *78*(3), 244–246. doi:10.1001/jamapsychiatry.2020.2588
- VanderWeele, T. J., Jackson, J. W., & Li, S. (2016). Causal inference and longitudinal data: A case study of religion and mental health. *Social Psychiatry and Psychiatric Epidemiology*, *51*(11), 1457–1466. doi:10.1007/s00127-016-1281-9
- van Gennip, A. C. E., Sedaghat, S., Carnethon, M. R., Allen, N. B., Klein, B. E. K., Cotch, M. F., ... van Sloten, T. T. (2022). Retinal microvascular caliber and incident depressive symptoms: The multi-ethnic study of atherosclerosis. *American Journal of Epidemiology*, *191*(5), 843–855. doi:10.1093/aje/kwab255
- Vatcheva, K. P., Lee, M., McCormick, J. B., & Rahbar, M. H. (2016). Multicollinearity in regression analyses conducted in epidemiologic studies. *Epidemiology (Sunnyvale)*, *6*(2), 227. doi:10.4172/2161-1165.1000227